Posted by Michael Wonder on 07 Jun 2018
The ICR responds to decision by NICE not to recommend abiraterone as first-line treatment for advanced prostate cancer
6 June 2018 - The Institute of Cancer Research, London, has expressed disappointment that the prostate cancer drug abiraterone (Zytiga) will not be made available to men with advanced prostate cancer as a first-line treatment on the NHS.
The Institute of Cancer Research (ICR) is calling for urgent discussions around the data supporting the drug’s effectiveness earlier in treatment and its price, and is urging a review of the decision within a year as new trial data become available.
Abiraterone was discovered at the ICR and developed in clinical trials with its hospital partner The Royal Marsden NHS Foundation Trust.
